Replies to post #71446 on Biotech Values

[DewDiligence]

GSK is not the only big-name partner—Archemix also has collaborations with PFE (#msg-16095415), ELN (#msg-12024629), and Merck Serono (#msg-20342372). Still, I don’t know enough about the company to opine on valuation. And I do agree that retaining NTMD’s CEO is suspect (#msg-33657360).

Quiz: What is the connection between Archemix and MNTA?

[DewDiligence]

Nice call on NTMD: Deerfield raised its offer to 0.80/sh and the BoD accepted. Inasmuch as 0.80 is more than Deerfield’s own estimate of liquidation value, the effective proceeds on Deerfield’s pre-deal shares could be considerably less than the 0.80 figure. As you said, Deerfield must have thought Archemix was a complete dog to have opted for this deal instead.

http://finance.yahoo.com/news/Archemix-Announces-Continued-bw-14169317.html

I can’t recall another deal where a buyer paid more than liquidation value in order to liquidate a company.

[DewDiligence]

Speaking of Archemix… they just replaced the CEO
(for obvious reasons, I suppose):

http://finance.yahoo.com/news/Archemix-Announces-Continued-bw-14169317.html